Supplementation with 18 downregulated the protein expression of iNOS, NF-κB, p-IκBα, IKKα and COX-2, reinforcing the contribution of nimbolide to the therapeutic strategy against RA [99]. This evidence concerns the gene NFKB1 and rheumatoid arthritis.